Saracatinib
- Generic Name
- Saracatinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C27H32ClN5O5
- CAS Number
- 379231-04-6
- Unique Ingredient Identifier
- 9KD24QGH76
- Background
Saracatinib has been investigated for the treatment of Cancer, Osteosarcoma, Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer.
- Associated Conditions
- -
- Associated Therapies
- -
Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Phase 2
Completed
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell CarcinomaRecurrent Metastatic Squamous Neck Cancer With Occult PrimaryRecurrent Squamous Cell Carcinoma of the HypopharynxStage III Squamous Cell Carcinoma of the Lip and Oral CavityRecurrent Squamous Cell Carcinoma of the LarynxRecurrent Squamous Cell Carcinoma of the Lip and Oral CavityRecurrent Squamous Cell Carcinoma of the NasopharynxRecurrent Squamous Cell Carcinoma of the OropharynxRecurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal CavityRecurrent Verrucous Carcinoma of the Larynx
- Interventions
- Drug: saracatinibOther: laboratory biomarker analysis
- First Posted Date
- 2007-08-08
- Last Posted Date
- 2014-04-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 9
- Registration Number
- NCT00513435
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
AZD0530 (NSC 735464) in Treating Patients With Previously Treated Metastatic Colon Cancer or Rectal Cancer
Phase 2
Terminated
- Conditions
- Adenocarcinoma of the RectumStage IV Rectal CancerRecurrent Rectal CancerStage IV Colon CancerAdenocarcinoma of the ColonRecurrent Colon Cancer
- Interventions
- Drug: saracatinibOther: laboratory biomarker analysis
- First Posted Date
- 2006-11-10
- Last Posted Date
- 2019-08-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 10
- Registration Number
- NCT00397878
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath